Company Name
The United Laboratories International Holdings Limited
Year of Establishment
1990
Enterprise Size
more than 1000
Annual Turnover(USD)
More than 99,999,999
Company Introduction
TUL was established in Hong Kong in 1990, which is a leading integrated pharmaceutical group company in China that researches, develops, manufactures, markets bulk medicines and intermediate products as well as finished products. Through more than 3 decades of development in China, TUL has grown into one of the largest antibiotics manufacturers in the world. TUL has 6 subsidiary plants nationwide across China altogether with employees totaling more than 10,000, whose products have been sold in 5 continents up to 60 countries. June 15,2007 saw TUL successfully listed in Hong Kong exchange(03933.HK.
So far, Dozens of products by TUL have passed certification of EU-GMP, FDA, China GMP.
Looking ahead, TUL stays committed to be in a pursuit of an objective of provision of superior quality medicines and products, aspiring with a dedication to promotion of the well-being of millions of people within China and around the world. We are energized by our pursuit, because we know significance of the mission we pursue: “ to make life more valuable”.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
http://www.tul.com.cn/
Other Competitive Advantages
1.Excellent enterprise in environmental protection
2.The sales network has expanded across the world
3.Keen on public welfare
4.State-of-the air manufacturing equipment
5.Listed on Hong Kong union stock exchange. Vertical integrated management for 6 production bases.
6.One of the largest antibiotics manufacturers in China.
7.Export Sales of antibiotic APIs ranks first in China; accredited as one of top 10 anti-infective drug brands in pharmaceutical industry in China.
8.“Scientific Research Post-doctor Workstation” awarded by ministry of personnel of China
Patents and Copyright
None
Milestone
In early 1990s, Hong Kong United Laboratories Co., Ltd. entered mainland China and established Zhuhai United Laboratories Co., Ltd.
In 1994, United Lab China Marketing Division was established and staffed a young and high-quality team with abundant marketing-related knowledge and expertise, and over 20 offices were opened in large and medium-size cities nationwide, stretching the sales network to every corner in China.
In 1994, Zhongshan Preparation Factory was established, which comprises a preparation factory, an API factory and Kingly Capsules Factory, wherein the preparation factory occupies an area of 60,000 m2, and API factory 250,000 m2.
In 1998, Zhuhai API Factory was completed. Occupying an area of 250,000 m2 with a greening rate of about 40%, it is a large-scale modernized and high-technology synthetic pharmaceutical enterprise mainly engaged in the production of semi-synthetic antibiotic APIs and passed the national GMP certification in July of the same year.
In 2003, Chengdu United Labratories Co., Ltd. was established and the "medical intermediate" production site was set up.
In 2006, the amoxicillin workshop became the first workshop in China that passes German GMP certification.
In 2007, the plant of The United Laboratories (Inner Mongolia) Co., Ltd. was built up and put into production.
On June 15, 2007, the United Laboratories International Holdings Limited was listed on Hong Kong Stock Exchange.
In 2010, the recombinant human insulin developed by United Lab obtained the production approval of China Food and Drug Administration and was marketed successfully in the trade name of USLIN.
In July 2011, United Lab "Amoxy" was recognized as the national famous brand.
At 16:08, April 15, 2013, Mr. Cai Jinle, a famous industrialist, founder of United Lab and Board Chairman of The United Laboratories International Holdings Limited died from disease at Hong Kong Union Hospital at the age of 72.
In June 2014, the United Lab established the sixth wholly-owned subsidiary, Jingui Pharmaceutical Co., Ltd. amid its efforts to explore the field of veterinary medicinal products.
On April 6, 2015, The United Laboratories (Inner Mongolia) Co., Ltd. passed the site inspection by FDA.
On May 13, 2017, the insulin glargine USLEN was put on the market.